Key result
Older men with prostate cancer residing in rural areas had a 28% higher risk of prostate cancer-specific mortality (SHR 1.28) and a 15% higher risk of all-cause mortality compared to metropolitan patients.
Why the study?
Rural areas have higher cardiovascular disease incidence and mortality in the general population, but the impact of rurality on cardiovascular outcomes in prostate cancer patients was unclear.
Does rurality status increase the risk of cardiovascular events and mortality in older men with prostate cancer?
Cohort (n=103,327)
Does rurality status increase the risk of cardiovascular events and mortality in older men with prostate cancer?
Hazard Ratio: 1.28 (95% CI 1.14–1.44)
Rural residency and receiving care from nonmetropolitan providers are associated with higher risks of prostate cancer-specific and all-cause mortality in older men with prostate cancer.
Rural residence linked to higher prostate cancer mortality; leaves open whether access interventions narrow disparities.
BACKGROUND: Rural areas have higher cardiovascular disease (CVD) incidence and age-adjusted mortality rates in the general population. However, the impact of rurality on CVD development and outcomes in patients with prostate cancer (PC) remains unclear. PATIENTS AND METHODS: This retrospective cohort study used the SEER-Medicare database to analyze males aged ≥65 years diagnosed with PC between 2009 and 2017. The primary exposures were patient rurality status (metropolitan, urban, or rural) and patient-provider rurality, which combined the provider's status (metropolitan vs nonmetropolitan) with the patient's rurality. The primary outcomes included post-PC CVD (comprising heart failure, atrial fibrillation, acute myocardial infarction, peripheral artery disease, and ischemic stroke), cardiovascular mortality (CVDm), prostate cancer-specific mortality (PCSm), and all-cause mortality. Multivariable Fine-Gray and extended Cox models were used to assess the impact of rurality impact on these outcomes. RESULTS: A total of 103,327 older men were included in the study, of whom 3,631 were from rural areas and 1,857 were rural patients with nonmetropolitan providers. Compared with metropolitan patients, those from rural areas had a 28% higher risk of PCSm (subdistribution hazard ratio [SHR], 1.28; 95% CI, 1.14-1.44) and a 15% higher risk of all-cause mortality (adjusted hazard ratio [aHR], 1.15; 95% CI, 1.07-1.23). Compared with urban patients, rural patients had a 7% higher risk of CVD (SHR, 1.07; 95% CI, 1.01-1.13). No significant differences were observed in CVDm. Among patients receiving androgen deprivation therapy (n=16,811), rurality was associated with a 27% higher risk of PCSm (SHR, 1.27; 95% CI, 1.07-1.51) and a 29% higher risk of all-cause mortality (aHR, 1.29; 95% CI, 1.12-1.49). Rural patients who received care from nonmetropolitan providers had higher risks of PCSm and all-cause mortality compared with those treated by metropolitan providers. CONCLUSIONS: Rurality is associated with higher risks of CVD, PCSm, and all-cause mortality compared with metropolitan and urban patients. Provider rurality further increases these risks, underscoring the critical role of health care access and quality in rural health disparities.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2025) conducted a cohort in Prostate cancer (n=103,327). Rural residency vs. Metropolitan residency was evaluated on Prostate cancer-specific mortality (PCSm) (SHR 1.28, 95% CI 1.14-1.44). Older men with prostate cancer residing in rural areas had a 28% higher risk of prostate cancer-specific mortality (SHR 1.28) and a 15% higher risk of all-cause mortality compared to metropolitan patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: